Publications:

Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation.

Journal Of Medicinal Chemistry

Beneker, Chad M CM; Rovoli, Magdalini M; Kontopidis, George G; Röring, Michael M; Galda, Simeon S; Braun, Sandra S; Brummer, Tilman T; McInnes, Campbell C

Publication Date: 2019-04-25

Variant appearance in text: BRAF: R509A

PubMed Link: 30977659

Variant Present in the following documents:

• Main text

View BVdb publication page

N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers.

Journal Of Medicinal Chemistry

Grasso, Michael M; Estrada, Michelle A MA; Berrios, Kiara N KN; Winkler, Jeffrey D JD; Marmorstein, Ronen R

Publication Date: 2018-06-14

Variant appearance in text: BRAF: R509A

PubMed Link: 29727562

Variant Present in the following documents:

• Main text

View BVdb publication page

Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.

The Embo Journal

Röring, Michael M; Herr, Ricarda R; Fiala, Gina J GJ; Heilmann, Katharina K; Braun, Sandra S; Eisenhardt, Anja E AE; Halbach, Sebastian S; Capper, David D; von Deimling, Andreas A; Schamel, Wolfgang W WW; Saunders, Darren N DN; Brummer, Tilman T

Publication Date: 2012-05-30

Variant appearance in text: BRAF: R509A

PubMed Link: 22510884

Variant Present in the following documents:

• Main text

View BVdb publication page